J Korean Ophthalmol Soc.  2012 Jun;53(6):792-800.

Depression and Anxiety in Korean Patients with Age-Related Macular Degeneration

• Jung JW
• Moon YS

Abstract

PURPOSE
To examine the degree of depression and anxiety in Korean patients with age-related macular degeneration (AMD) and to evaluate the influence of mood disturbance on patient's treatment satisfaction and compliance.
METHODS
Forty-four patients with AMD and thirty-three controls comprised the study populations. Patients and controls rated themselves on the Korean Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI). The effect of mood disturbance on the patient's satisfaction and compliance was evaluated.
RESULTS
The depression and anxiety scores were significantly higher in patients with AMD. The mood disturbance was negatively correlated with the patient's satisfaction and compliance. 14 patients (31.8%) were lost to follow-up 1 year later. The depression and anxiety scores of these patients were higher than those of remaining thirty patients.
CONCLUSIONS
Depression and anxiety of patients with AMD affect on patient's satisfaction and compliance. So recognition and management of mood disturbance may help improving visual function and maintaining quality of life in patients.

Keyword

Age-related macular degeneration; Anxiety; Compliance; Depression; Satisfaction

MeSH Terms

Anxiety
Compliance
Depression
Humans
Lost to Follow-Up
Macular Degeneration
Quality of Life

Figure

• 

  Figure 1 Effect of profile of Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI) on treatment compliance in patients with AMD. Compliant: maintenance of follow up, n = 30 / Uncompliant: loss of follow up, n = 14. Unpaired t-test was performed. *p-value <0.05 statistically significant.

Reference

1. Congdon N, O'Colmain B, Klaver CC, et al. Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004. 122:477–485.

2. Friedman DS, O'Colmain BJ, Muñoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004. 122:564–572.

3. Rein DB, Wittenborn JS, Zhang X, et al. Vision Health Cost-Effectiveness Study Group. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch Ophthalmol. 2009. 127:533–540.

4. Youm DJ, Oh HS, Yu HG, Song SJ. The prevalence of vitreoretinal diseases in a screened Korean population 50 years and older. J Korean Ophthalmol Soc. 2009. 50:1645–1651.

5. Park KH, Song SJ, Lee WK, et al. The results of nation-wide registry of age-related macular degeneration in Korea. J Korean Ophthalmol Soc. 2010. 51:516–523.

6. Slakter JS, Stur M. Quality of life in patients with age-related macular degeneration: impact of the condition and benefits of treatment. Surv Ophthalmol. 2005. 50:263–273.

7. Casten RJ, Rovner BW, Tasman W. Age-related macular degeneration and depression: a review of recent research. Curr Opin Ophthalmol. 2004. 15:181–183.

8. Augustin A, Sahel JA, Bandello F, et al. Anxiety and depression prevalence rates in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2007. 48:1498–1503.

9. Rovner BW, Casten RJ, Massof RW, et al. Psychological and cognitive determinants of vision function in age-related macular degeneration. Arch Ophthalmol. 2011. 129:885–890.

10. Rees G, Tee HW, Marella M, et al. Vision-specific distress and depressive symptoms in people with vision impairment. Invest Ophthalmol Vis Sci. 2010. 51:2891–2896.

11. Mathew RS, Delbaere K, Lord SR, et al. Depressive symptoms and quality of life in people with age-related macular degeneration. Ophthalmic Physiol Opt. 2011. 31:375–380.

12. Casten R, Rovner B. Depression in age-related macular degeneration. J Vis Impair Blind. 2008. 102:591–599.

13. Casten R, Rovner BW, Leiby BE, Tasman W. Depression despite anti-vascular endothelial growth factor treatment of age-related macular degeneration. Arch Ophthalmol. 2010. 128:506–508.

14. Nielsen AC 3rd, Williams TA. Prevalence by self-report questionnaire and recognition by nonpsychiatric physicians. Arch Gen Psychiatry. 1980. 37:999–1004.

15. Rhee MK, Lee YH, Park SH, et al. A standardization study of Beck depression inventory I; Korean version (K-BDI): reliability and factor analysis. Korean J Psychopathol. 1995. 4:77–95.

16. Seo SK. Relationship between self-discrepancy and depression or anxiety with consideration of self-focused attention, actual self-concept, and self-guides preference. 1996. Seoul: Department of Psychology, Graduate School of Seoul National University;[Master's Thesis].

17. Chang TS, Bressler NM, Fine JT, et al. MARINA Study Group. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 2007. 125:1460–1469.

18. Owsley C, McGwin G Jr. Depression and the 25-item National Eye Institute Visual Function Questionnaire in older adults. Ophthalmology. 2004. 111:2259–2264.

19. Miskala PH, Bressler NM, Meinert CL. Relative contributions of reduced vision and general health to NEI-VFQ scores in patients with neovascular age-related macular degeneration. Arch Ophthalmol. 2004. 122:758–766.

20. Cubo E, Bernard B, Leurgans S, Raman R. Cognitive and motor function in patients with Parkinson's disease with and without depression. Clin Neuropharmacol. 2000. 23:331–334.

21. Brody BL, Gamst AC, Williams RA, et al. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology. 2001. 108:1893–1900.

22. Paz SH, Globe DR, Wu J, et al. Relationship between self-reported depression and self-reported visual function in Latinos. Arch Ophthalmol. 2003. 121:1021–1027.

23. Rovner BW, Casten RJ, Tasman WS. Effect of depression on vision function in age-related macular degeneration. Arch Ophthalmol. 2002. 120:1041–1044.

24. Watson M, Haviland JS, Greer S, et al. Influence of psychological response on survival in breast cancer: a population-based cohort study. Lancet. 1999. 354:1331–1336.

25. Frasure-Smith N, Lespérance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation. 1995. 91:999–1005.

26. Barefoot JC, Brummett BH, Helms MJ, et al. Depressive symptoms and survival of patients with coronary artery disease. Psychosom Med. 2000. 62:790–795.

27. Carney C. Diabetes mellitus and major depressive disorder: an overview of prevalence, complications, and treatment. Depress Anxiety. 1998. 7:149–157.

28. Jeon BH, Kim HW, Kim HJ, et al. The relationship of anxiety symptoms and depressive symptoms to glycemic control in diabetic patients. Korean J Psychosom Med. 2008. 16:95–102.

29. Brody BL, Roch-Levecq AC, Thomas RG, et al. Self-management of age-related macular degeneration at the 6-month follow-up: a randomized controlled trial. Arch Ophthalmol. 2005. 123:46–53.

30. Kandula S, Lamkin JC, Albanese T, Edward DP. Patient's knowledge and perspectives on wet age-related macular degeneration and its treatment. Clin Ophthalmol. 2010. 4:375–381.